Ruxolitinib Adverse Event Data and Strategies for Managing Side Effects
Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.
EP: 1.Introduction: A 58-Year-Old Man With Moderate Steroid-Refractory cGVHD and Risk Factors for cGVHD
EP: 2.Overview of cGVHD Symptoms, Diagnosis, and Tools for Severity Assessment
EP: 3.Steroid-Refractory cGVHD: Risk Factors and Clinical Challenges
EP: 4.Treatment Options for Steroid-Refractory cGVHD
EP: 5.Ruxolitinib in Steroid-Refractory cGVHD and REACH3 Efficacy Data
EP: 6.Real-World Efficacy Data for Ruxolitinib in Steroid-Refractory cGVHD
EP: 7.Ruxolitinib Adverse Event Data and Strategies for Managing Side Effects
EP: 8.Case Commentary and Considerations for Treatment and Management
EP: 9.Future Directions in GVHD
Case: A 58-Year-Old Man With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
- A 58-year-old man previously underwent myeloablative conditioning and an allogeneic PBSC transplant for acute lymphocytic leukemia
- Received tacrolimus and methotrexate for GVHD prophylaxis
- At 10 months post-transplant, patient developed moderate muscle and joint pain with decreased range of motion, mild erythematous rash on cheeks
First-line Treatment
- Patient received topical steroid cream for rash, and was started on oral prednisone at 1 mg/kg/day
- After 4 weeks of treatment, the patient’s rash resolved but muscle/joint pain continued
Second-line Treatment
- Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
BLA for Remestemcel-L to Treat Pediatric SR-aGVHD Resubmitted to FDA
July 10th 2024The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.
Read More
Novel Therapy Boosts Survival After Stem Cell Transplants
July 3rd 2024Alexandra Gomez Arteaga, MD, discussed findings from a retrospective study comparing Orca-T with posttransplant cyclophosphamide graft-vs-host disease prophylaxis to assess outcomes in patients undergoing hematopoietic cell transplant.
Read More
Ponatinib, Chemo, and Transplant Shows Promise for Long-Term Survival in Ph+ ALL
June 20th 2024The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
